CLINICAL TRIALS PROFILE FOR VISKEN

All Clinical Trials for VISKEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00424801 ↗	Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris	Terminated	Danish Cardiovascular Research Academy	N/A	2007-01-01	The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris
NCT00424801 ↗	Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris	Terminated	Danish Heart Foundation	N/A	2007-01-01	The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris
NCT00424801 ↗	Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris	Terminated	Novartis	N/A	2007-01-01	The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris
NCT00424801 ↗	Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris	Terminated	University of Aarhus	N/A	2007-01-01	The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris
NCT01400165 ↗	Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations	Unknown status	University of Ottawa	Phase 1	2011-07-01	Generic describes a pharmaceutical product that does not have a brand name or trademark. Generic medications should be the equivalent of brand medications. Only their price should be different. The active ingredient of the generic medication has to be within a window of 80 to 125% of the original in the blood. There are reports that this standard is not always followed after the medication has been on the market. Indeed, it was observed that some patients previously stable on original medications relapsed when switched to a generic. Several factors could account for this problem. Such problems have been reported for Pindolol, Quetiapine, and Trazodone. Some properties of specific brands of the generics and the original brands will be examined for these three medications. The three original medications used in this study are the Visken, the Seroquel, and the Desyrel. The three generics are the Teva-pindolol, the Teva-Quetiapine, and the Teva-Trazodone. They are all available on the Canadian market by prescription.

Clinical Trial Conditions for VISKEN

Condition Name

Condition Name for VISKEN
Intervention	Trials
Healthy	1
Hypertension	1
Microvascular Angina	1

Condition MeSH

Condition MeSH for VISKEN
Intervention	Trials
Microvascular Angina	1
Angina Pectoris	1

Clinical Trial Locations for VISKEN

Trials by Country

Trials by Country for VISKEN
Location	Trials
Canada	1
Denmark	1

Clinical Trial Progress for VISKEN

Clinical Trial Phase

Clinical Trial Phase for VISKEN
Clinical Trial Phase	Trials
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for VISKEN
Clinical Trial Phase	Trials
Unknown status	1
Terminated	1

Clinical Trial Sponsors for VISKEN

Sponsor Name

Sponsor Name for VISKEN
Sponsor	Trials
University of Aarhus	1
University of Ottawa	1
Danish Cardiovascular Research Academy	1

Sponsor Type

Sponsor Type for VISKEN
Sponsor	Trials
Other	4
Industry	1